Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. IPOPEMA Securities's accounts receivables for the quarter that ended in Mar. 2026 was zł263.0 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
IPOPEMA Securities's Days Sales Outstanding for the quarter that ended in Mar. 2026 was 354.78.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. IPOPEMA Securities's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was zł-7.57.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
IPOPEMA Securities's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), IPOPEMA Securities's accounts receivable are only considered to be worth 75% of book value:
IPOPEMA Securities's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
IPOPEMA Securities Accounts Receivable Related Terms
IPOPEMA Securities Accounts Receivable Historical Data
* Premium members only.
The historical data trend for IPOPEMA Securities's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of zł263.0 Mil mean?
IPOPEMA Securities (WAR:IPE) has a Accounts Receivable of zł263.0 Mil as of Mar. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on IPOPEMA Securities and its competitors.
Is IPOPEMA Securities' Accounts Receivable too high?
IPOPEMA Securities' current Accounts Receivable is zł263.0 Mil. Overall, IPOPEMA Securities has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IPOPEMA Securities' Accounts Receivable compare to MS and GS?
IPOPEMA Securities' Accounts Receivable of zł263.0 Mil can be compared against companies in the Capital Markets industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Capital Markets company?
A good Accounts Receivable depends on the Capital Markets industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on IPOPEMA Securities and its competitors. IPOPEMA Securities's current Accounts Receivable is zł263.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IPOPEMA Securities stock overvalued right now?
Based on GuruFocus' analysis, IPOPEMA Securities (WAR:IPE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł3.63, compared to a current price of zł8.92 — trading 145.7% above its estimated fair value. The current Accounts Receivable is zł263.0 Mil. IPOPEMA Securities' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For IPOPEMA Securities (WAR:IPE), the current Accounts Receivable is zł263.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IPOPEMA Securities (WAR:IPE) Overvalued in 2026?
Based on GuruFocus' analysis, IPOPEMA Securities stock appears to be overvalued.
The current stock price of zł8.92 is trading 145.7% above its estimated GF Value™ of zł3.63.
GuruFocus considers IPOPEMA Securities to be Significantly Overvalued.
Key valuation signals for WAR:IPE:
Accounts Receivable: zł263.0 Mil
GF Value™: zł3.63 vs. price of zł8.92 (145.7% above fair value)
No single metric tells the full story. See the WAR:IPE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IPOPEMA Securities SA is focused on brokerage activities, Business and management consulting, running an investment fund company and creating and managing investment funds, Management of portfolios of brokerage financial instruments, IT management activities, and IT consulting activities. It specializes in brokerage and company analysis services, investment banking services, as well as the distribution of investment products and investment advisory services addressed to a wide range of individual investors, the creation and management of closed-end and open-end investment funds and asset management, as well as business and IT consulting services.
57GF Score
Get the complete analysis for WAR:IPE
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:IPE has been successfully added to your 
